3BBLACKBIO3B Blackbio Dx Ltd.

    3B Blackbio Dx Q2 FY27 Results: Consolidated Net Profit ₹18.02 Crore on Total Income of ₹52.99 Crore

    • Earnings
    • Agrochemicals and molecular diagnostics
    Laboratory glassware: flasks, a funnel and a measuring cylinder
    Illustrative image. Photo: Medicuspetrus, via Wikimedia Commons (public domain)

    3B Blackbio Dx (NSE: 3BBLACKBIO) reported consolidated total income of ₹52.99 crore and net profit of ₹18.02 crore for the quarter ended 30 Sep 2026, and standalone total income of ₹38.97 crore and net profit of ₹17.96 crore, it said in a filing on 13 Nov 2026.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹52.99 crore, up 34.5% YoY and 33.7% QoQ
    • Net profit and EPS: Net profit ₹18.02 crore, up 19.9% YoY; basic EPS ₹21.03
    • Revenue from operations: ₹48.28 crore, up 42.4% YoY; other income ₹4.71 crore, down 14.5% YoY

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹38.97 crore, up 22.4% YoY and 38.0% QoQ
    • Net profit and EPS: Net profit ₹17.96 crore, up 20.2% YoY; basic EPS ₹20.96
    • Other income: ₹2.46 crore, down 37.1% YoY

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    52.9939.41+34.5%39.63+33.7%
    18.0215.04+19.9%8.97+100.8%
    EPS, basic (₹)21.0317.55+19.8%10.48+100.7%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Income grew faster than profit on a year-on-year basis. Consolidated total income rose 34.5% to ₹52.99 crore, while net profit rose 19.9% to ₹18.02 crore. Revenue from operations rose 42.4%, and other income fell 14.5% to ₹4.71 crore, which is 8.9% of total income this quarter.

    Against the previous quarter the picture is different. Net profit more than doubled, rising 100.8% from ₹8.97 crore, while total income rose 33.7%. Consolidated tax expense of ₹6.27 crore is 25.8% of profit before tax of ₹24.30 crore, compared with ₹4.58 crore a year earlier on profit before tax of ₹19.62 crore.

    Depreciation rose to ₹1.41 crore from ₹0.58 crore a year earlier, and finance costs remained small at ₹0.06 crore. The filing reports two subsidiaries, Coris Holding SRL, Belgium and TRUPCR Europe Limited, and the auditor says their unaudited results are not material to the group. Consolidated net profit attributable to owners was ₹17.80 crore, against ₹18.02 crore for the period before minority interests.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    38.9731.82+22.4%28.25+38.0%
    17.9614.94+20.2%14.11+27.3%
    EPS, basic (₹)20.9617.44+20.2%16.47+27.3%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Standalone total income rose 22.4% to ₹38.97 crore, with revenue from operations up 30.8% to ₹36.51 crore. Other income fell 37.1% to ₹2.46 crore, or 6.3% of total income. Net profit rose 20.2% to ₹17.96 crore, slower than profit before tax, which rose 24.1% to ₹24.23 crore.

    Standalone tax expense was ₹6.27 crore, 25.9% of profit before tax, up from ₹4.58 crore a year earlier. Standalone exceptional items were nil in the quarter. Finance costs were nil against ₹0.01 crore a year earlier.

    The company describes its agrochemical business as seasonal, with performance that can be affected by weather conditions and cropping pattern. Its two reportable segments are Agrochemicals and Molecular Diagnostic Kits.

    Inference

    The filing reports the board's approval of the results on 13 Nov 2026 and a limited review by the statutory auditor, Baheti & Co., with no modification noted in the review conclusions. The company also reports a standalone equity dividend paid of ₹4.28 crore in the half year.

    The filing does not say what drove the rise in total income or the change in consolidated tax expense, which equals the standalone current tax figure. A reader would also want to know the reason for the difference between consolidated and standalone profit before tax; the filing does not give it.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Latest posts